SS Innovations International Inc. filings document a Nasdaq-listed surgical robotics issuer and its formal disclosures around the SSi Mantra platform. Recent Current Reports on Form 8-K record product and regulatory updates, telesurgery announcements, conference-related disclosures, financial-results releases and Regulation FD communications.
The filing record also covers capital structure events, including an unregistered private placement of common stock, and identifies the company’s common stock as registered on Nasdaq under SSII. Annual-report and current-report disclosures provide formal context for operating results, product development, clinical and regulatory timelines, forward-looking statements, and the company’s subsidiary-based reporting perimeter.
SS Innovations International, Inc. insider reporting shows an "other" type transaction involving indirect holdings associated with Chairman and CEO Sudhir Srivastava. An entity he controls, Sushruta Pvt. Ltd., transferred 21,506 shares of common stock at $5.0000 per share.
The transfer was made pursuant to a settlement agreement dated May 4, 2026. After this restructuring, Sushruta Pvt. Ltd. is reported as holding 109,564,261 shares of SS Innovations common stock indirectly for Srivastava, indicating the transaction is very small relative to his overall position.
SS Innovations International, Inc. reported record unaudited first quarter 2026 revenue of $11.1 million, up about 117% from $5.1 million a year earlier, driven mainly by higher SSi Mantra system and instrument sales. System sales rose to $9.6 million and instruments to $1.2 million, while total revenue increased 116.8%.
Gross profit expanded to $5.3 million from $1.1 million. The company still posted a net loss of $3.6 million, but this improved from a $5.7 million loss in the prior-year quarter as operating loss narrowed. Installations of the SSi Mantra system grew to 26 in the quarter, with a cumulative installed base of 194 systems and 1,859 surgeries performed.
Liquidity strengthened significantly. Cash flows from financing activities included $18.6 million in gross proceeds from a March 2026 private placement, contributing to cash and cash equivalents of $24.0 million at March 31, 2026. Management highlighted ongoing regulatory efforts, including U.S. FDA review of a 510(k) submission and progress toward European Union CE marking for the SSi Mantra.
SS Innovations International, Inc. reported strong top-line growth but continued losses for the three months ended March 31, 2026. Revenue rose to $11,101,366 from $5,120,610 a year earlier, driven mainly by higher system sales.
The company posted a net loss of $3,582,571, improving from a $5,681,353 loss, with results heavily affected by non-cash stock compensation of $3,144,315 and depreciation of $323,747. Cash, cash equivalents and restricted cash increased to $24,005,680, helped by a private placement that generated net proceeds of $18,446,498.
Despite a working capital surplus of $40,216,514, management disclosed that recurring losses, dependence on related-party funding, and insufficient projected cash flows raise substantial doubt about the company’s ability to continue as a going concern over the next 12 months, absent additional financing and successful execution of growth plans.
SS Innovations International, Inc. reported a milestone demonstration of its robotic telesurgery technology. The company announced a successful long-distance cross-border procedure using the SSi Mantra surgical robotic system and the SSi MantrAsana tele-surgeon console, connecting a surgeon in Perth, Australia with a patient in Indore, India over more than 4,500 miles.
On May 2, 2026, Dr. Mohit Bhandari remotely performed a robotic gastrojejunostomy during the Royal Australian College of Surgeons Annual Scientific Congress using the portable SSi MantrAsana console. The company notes that more than 170 telesurgeries, including complex cardiac procedures, have now been completed with SSi Mantra, which has been clinically validated in India in over 100 types of surgical procedures.
SS Innovations International, Inc. reported that more than 10,500 cumulative surgeries have been successfully performed using its SSi Mantra surgical robotic system as of April 30, 2026. These include over 500 cardiac procedures, 170 telesurgeries, and 125 pediatric surgeries across multiple specialties.
The company has installed more than 200 SSi Mantra systems in eleven countries and trained approximately 2,100 physicians, with the platform used in over 170 different procedure types. Management highlights technology features, user-friendliness, and cost advantages as drivers of adoption since commercial launch in August 2022.
SS Innovations International, Inc. reports amended beneficial ownership by Sudhir Srivastava and Sushruta PVT LTD. Sudhir Srivastava beneficially owns 114,490,054 shares, representing 55.8% of the outstanding common stock. Sushruta PVT LTD holds 109,585,767 shares, representing 54.7%. The percentages are calculated using 200,231,535 shares outstanding as of March 9, 2026, per the company’s amended Form 10-K/A. The filing states Dr. Srivastava has a 100% interest in Sushruta PVT LTD and that his reported position includes options to purchase 4,872,287 shares and a direct holding of 32,000 shares.
SS Innovations International, Inc. filed a shelf S-3 registration to offer up to $150,000,000 of securities and to register up to 5,016,500 shares of common stock for resale by selling shareholders. The 5,016,500 Shares include 4,474,833 issued in a March 6, 2026 private placement and shares underlying warrants of 41,667 (RCP Warrants, $3.45 exercise) and 500,000 (HCW Warrants, $8.89 exercise). The prospectus states the company will not receive proceeds from selling shareholders’ resale; proceeds to the company will arise only if the warrants are exercised. The company reports a Nasdaq close of $4.02 on April 30, 2026 and that Chairman/CEO Dr. Sudhir Srivastava, through Sushruta Pvt Ltd., beneficially controls approximately 55.85% of the voting power.
SS Innovations International, Inc. filed an 8-K to share a press release about its vision for new surgical robotic technologies unveiled at the Global Multi-Specialty Robotic Surgery Conference (SMRSC 2026) in New Delhi, India, which the Company recently hosted.
The Company highlighted four main innovations under development: the SSi Vimana Aero drone-based surgical system, the SSi Avtara humanoid surgical platform, the SSi Operion mobile operating room, and new single-arm robotic endoscopy and ultrasound assist carts. These concepts emphasize remote, mobile and teleoperated care in challenging environments.
At SMRSC 2026, more than 1,600 in-person and 1,800 virtual participants from 19 nations attended. Expert physicians performed 10 live telesurgeries and 13 live robotic surgeries using the Company’s existing SSi Mantra system across multiple specialties. The filing also reiterates standard forward-looking statement cautions.
SS Innovations International, Inc. Chairman and CEO Sudhir Srivastava reported an indirect transfer of 10,000 shares of common stock as a bona fide gift. The shares were held by Sushruta Pvt. Ltd., an entity in which he has a controlling interest.
Following this non-market gift transaction, entities associated with Srivastava indirectly hold 109,585,767 shares of SS Innovations common stock. The filing reflects a routine personal transfer with no sale proceeds or open-market trading activity.